Atsena’s ATSN-201 and ATSN-101 Show Sustained Efficacy in Gene Therapy Trials
Atsena's ATSN-201 and ATSN-101 show sustained efficacy in gene therapy trials with zero serious adverse events through 36 months.
Artiva’s AlloNK Shows 54% ACR50 Response Rate in Refractory Rheumatoid Arthritis
Artiva's AlloNK achieves 54% ACR50 response in refractory rheumatoid arthritis patients, outpacing rituximab alone in early trial data.
Celldex Completes Enrollment of 1,939 Patients in Barzolvolimab Phase 3 Trials
Celldex completes barzolvolimab Phase 3 enrollment of 1,939 patients across two trials, advancing topline data to Q4 2026.
FDA Approves Efgartigimod for All Adult Myasthenia Gravis Types
FDA approves efgartigimod for all adult myasthenia gravis types, including seronegative patients previously excluded from treatment options.
4DMT Completes 4FRONT-1 Randomization With $458M Cash for 2027 Data
4DMT completes 4FRONT-1 randomization of all 523 participants with topline data expected in H1 2027, backed by $458M cash...
Atsena’s ATSN-201 and ATSN-101 Gene Therapies Show Durability in Phase 2 Data
Atsena's ATSN-201 and ATSN-101 gene therapies demonstrate sustained structural and functional improvements at 12 and 36 months in Phase...
Rapport’s RAP-219 Shows 22-Day Half-Life, Reshapes Phase 3 Design
RAP-219's revised 22-day half-life extends seizure control weeks past treatment and reshapes Phase 3 design for focal onset seizures.
Celldex’s Phase 3 CSU Trial Enrolls 1,939 Patients Six Months Ahead of Plan
Celldex's Phase 3 CSU Trial enrolls 1,939 patients six months ahead of schedule, representing the largest randomized trial in...
Denali Pursues DNL593 Progranulin Replacement in FTD-GRN After Takeda Exit
Denali pursues DNL593 progranulin replacement in FTD-GRN after Takeda exit, with Phase 1/2 data expected by year-end in a...
Praxis Reports 77% Seizure Reduction in SCN2A Epilepsy Study
Praxis reported 77% placebo-adjusted seizure reduction in SCN2A epilepsy, with all treated patients showing improvements in sleep, motor function,...